rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Christopher Hite

EVP & Chairman, Partnering

Company insider

Files Form 4 as: EVP & Chairman, Partnering, Royalty Pharma; Director, Kailera Therapeutics; Director, Vera Therapeutics; Director, Acceleron Pharma.

Every Form 4 they filed

In numbers

Trades disclosed
48
Buys
1
Sells
4
Bought
$2.0M
Sold
$54.7M
Companies
4
Companies where not an officer
3
First trade
4 Jun 2020
Last trade
22 Sep 2026
Last filed
24 Sep 2026

Companies traded

Where they are an officer
RPRX Royalty PharmaOfficer · Pharmaceuticals · last 22 Sep 20261 buy · 4 sells
Everywhere else they filed: board seats, 10% stakes, other companies
KLRA Kailera TherapeuticsDirector · Biotechnology · last 16 Apr 20260 buys · 0 sells
VERA Vera TherapeuticsDirector · Biotechnology · last 5 Mar 20260 buys · 0 sells
Acceleron PharmaDirector · last 19 Nov 20210 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
20Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
22 Sep 2026filed 24 Sep 2026RPRX Royalty PharmaPharmaceuticalsSEC FORM 4 Sold$5.6M96,073 at $58.51filing
22 Sep 2026filed 24 Sep 2026RPRX Royalty PharmaPharmaceuticalsSEC FORM 4 Sold$231K3,927 at $58.93filing
22 Sep 2026filed 24 Sep 2026RPRX Royalty PharmaPharmaceuticalsSEC FORM 4 Sold$5.6M96,073 at $58.51filing
22 Sep 2026filed 24 Sep 2026RPRX Royalty PharmaPharmaceuticalsSEC FORM 4 Sold$231K3,927 at $58.93filing
19 Aug 2026filed 19 Aug 2026RPRX Royalty PharmaPharmaceuticalsSEC FORM 4 Code G—16,800 at $0.00filing
19 Aug 2026filed 19 Aug 2026RPRX Royalty PharmaPharmaceuticalsSEC FORM 4 Code G—16,800 at $0.00filing
18 Aug 2026filed 19 Aug 2026RPRX Royalty PharmaPharmaceuticalsSEC FORM 4 Sold$6.0M100,000 at $59.97filing
18 Aug 2026filed 19 Aug 2026RPRX Royalty PharmaPharmaceuticalsSEC FORM 4 Sold$6.0M100,000 at $59.97filing
5 Aug 2026filed 7 Aug 2026RPRX Royalty PharmaPharmaceuticalsSEC FORM 4 Code A—11,002 at $0.00filing
5 Aug 2026filed 7 Aug 2026RPRX Royalty PharmaPharmaceuticalsSEC FORM 4 Code A—11,002 at $0.00filing
30 Jun 2026filed 2 Jul 2026RPRX Royalty PharmaPharmaceuticalsSEC FORM 4 Sold$5.5M97,446 at $56.50filing
30 Jun 2026filed 2 Jul 2026RPRX Royalty PharmaPharmaceuticalsSEC FORM 4 Sold$146K2,554 at $57.10filing
30 Jun 2026filed 2 Jul 2026RPRX Royalty PharmaPharmaceuticalsSEC FORM 4 Sold$1.7M29,400 at $56.44filing
30 Jun 2026filed 2 Jul 2026RPRX Royalty PharmaPharmaceuticalsSEC FORM 4 Sold$34K600 at $57.09filing
30 Jun 2026filed 2 Jul 2026RPRX Royalty PharmaPharmaceuticalsSEC FORM 4 Sold$5.5M97,446 at $56.50filing
30 Jun 2026filed 2 Jul 2026RPRX Royalty PharmaPharmaceuticalsSEC FORM 4 Sold$146K2,554 at $57.10filing
30 Jun 2026filed 2 Jul 2026RPRX Royalty PharmaPharmaceuticalsSEC FORM 4 Sold$1.7M29,400 at $56.44filing
30 Jun 2026filed 2 Jul 2026RPRX Royalty PharmaPharmaceuticalsSEC FORM 4 Sold$34K600 at $57.09filing
23 Jun 2026filed 25 Jun 2026RPRX Royalty PharmaPharmaceuticalsSEC FORM 4 Sold$1.8M32,408 at $54.11filing
23 Jun 2026filed 25 Jun 2026RPRX Royalty PharmaPharmaceuticalsSEC FORM 4 Sold$6.4M117,592 at $54.47filing

Sectors

Health Care5

Buys in green, sells in red, by the company’s sector.

Related people

Marshall UristEVP, Research & Investments · EVP, Research & Investments at Royalty Pharma, filing Form 4 there in the last year
Bonnie L. BasslerDirector · Director at Royalty Pharma, filing Form 4 there in the last year
Terrance P. CoyneEVP & CFO · EVP & CFO at Royalty Pharma, filing Form 4 there in the last year
Pablo G. LegorretaCEO, Chairman of the Board · CEO, Chairman of the Board at Royalty Pharma, filing Form 4 there in the last year
Elizabeth H. WeathermanDirector · Director at Royalty Pharma, filing Form 4 there in the last year